Finally we discuss the benefit, feasibility and some strategic issues for developing BACE1 inhibitors primarily targeting at CAA, in addition the compounds designated to reduce amyloid plaque lesions explored currently in clinical trials. The gene discussed is BACE1; the disease is amyloidosis.